Skip to main content
Erschienen in: Diseases of the Colon & Rectum 11/2007

01.11.2007 | Original Contributions

Does Infliximab Infusion Impact Results of Operative Treatment for Crohn’s Perianal Fistulas?

verfasst von: Wolfgang B. Gaertner, M.D., Alejandra Decanini, M.D., Anders Mellgren, M.D., Ph.D., Ann C. Lowry, M.D., Stanley M. Goldberg, M.D., Robert D. Madoff, M.D., Michael P. Spencer, M.D.

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Infliximab is an effective treatment for active intestinal Crohn’s disease; however, the efficacy of infliximab in perianal Crohn’s disease is controversial. This study was designed to compare patients with Crohn’s disease who underwent perianal fistula surgery with or without infliximab infusion.

Methods

A retrospective chart review of 226 consecutive patients with Crohn’s disease who underwent operative treatment with or without infliximab (3- infusions of 5 mg/kg) from March 1991 through December 2005 was completed. Patients were classified as completely healed, minimally symptomatic (seton placement with minimal drainage and/or infliximab dependence), and failure (persistent or recurrent symptomatic fistula, diverting procedure, or proctectomy).

Results

A total of 226 patients underwent operative treatment alone (n--47) or in combination with infliximab infusion (n--9). Age, gender, and preoperative history of intestinal and perianal Crohn’s disease were similar between groups. Mean follow-up was 30 (range, 6-16) months. Operative treatment consisted of seton drainage (n--12), conventional fistulotomy (n--2), fibrin glue injection (n--4), advancement flap (n--), collagen plug insertion (n--), and transperineal repair (n--). Eighty-eight patients (60 percent) healed completely with operative treatment alone, and 47 patients (59 percent) healed after operative treatment in combination with infliximab (P- not significant).

Conclusions

Operative treatment of perianal fistulas in patients with Crohn’s disease resulted in complete healing in approximately 60 percent of patients. Preoperative infliximab infusion did not affect overall healing rates.
Literatur
1.
Zurück zum Zitat Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-0.CrossRefPubMed Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-0.CrossRefPubMed
2.
Zurück zum Zitat Williams JG, MacLeod CA, Rothenberger DA, Goldberg SM. Seton treatment of high anal fistulae. Br J Surg 1991;78:1159-1.CrossRefPubMed Williams JG, MacLeod CA, Rothenberger DA, Goldberg SM. Seton treatment of high anal fistulae. Br J Surg 1991;78:1159-1.CrossRefPubMed
3.
Zurück zum Zitat Sohn N, Korelitz BI, Weinstein MA. Anorectal Crohn’s disease: definitive surgery for fistulas and recurrent abscesses. Am J Surg 1980;139:394-.CrossRefPubMed Sohn N, Korelitz BI, Weinstein MA. Anorectal Crohn’s disease: definitive surgery for fistulas and recurrent abscesses. Am J Surg 1980;139:394-.CrossRefPubMed
4.
Zurück zum Zitat van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut 1997;40:443-.PubMed van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut 1997;40:443-.PubMed
5.
Zurück zum Zitat Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn’s and ulcerative colitis): a review. Dig Dis 1994;12:290–304.CrossRefPubMed Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn’s and ulcerative colitis): a review. Dig Dis 1994;12:290–304.CrossRefPubMed
6.
Zurück zum Zitat Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89–91.CrossRefPubMed Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89–91.CrossRefPubMed
7.
Zurück zum Zitat Reimund J-M, Wittershiem C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn’s disease. J Clin Immunol 1996;16:144-0.CrossRefPubMed Reimund J-M, Wittershiem C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn’s disease. J Clin Immunol 1996;16:144-0.CrossRefPubMed
8.
Zurück zum Zitat Breese EJ, Michie CA, Nicholls SW, et al. Tumour necrosis factor-a producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-6.PubMed Breese EJ, Michie CA, Nicholls SW, et al. Tumour necrosis factor-a producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-6.PubMed
9.
Zurück zum Zitat Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029-5.CrossRefPubMed Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029-5.CrossRefPubMed
10.
Zurück zum Zitat Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003;9:98–103.CrossRefPubMed Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003;9:98–103.CrossRefPubMed
11.
Zurück zum Zitat Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis 2005;7:164-.CrossRefPubMed Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis 2005;7:164-.CrossRefPubMed
12.
Zurück zum Zitat Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003;98:332-.CrossRefPubMed Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003;98:332-.CrossRefPubMed
13.
Zurück zum Zitat van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets-Tan RG, van Gemert WG. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn’s disease: a preliminary report. Dis Colon Rectum 2005;48:758-7.CrossRefPubMed van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets-Tan RG, van Gemert WG. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn’s disease: a preliminary report. Dis Colon Rectum 2005;48:758-7.CrossRefPubMed
14.
Zurück zum Zitat Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398-05.CrossRefPubMed Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398-05.CrossRefPubMed
15.
Zurück zum Zitat Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-5.CrossRefPubMed Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-5.CrossRefPubMed
16.
Zurück zum Zitat Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum 2003;46:577-3.CrossRefPubMed Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum 2003;46:577-3.CrossRefPubMed
17.
Zurück zum Zitat Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006;49:1837-1.CrossRefPubMed Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006;49:1837-1.CrossRefPubMed
18.
Zurück zum Zitat Nordgren S, Fasth S, Hulten L. Anal fistulas in Crohn’s disease: incidence and outcome of surgical treatment. Int J Colorectal Dis 1992;7:214-.CrossRefPubMed Nordgren S, Fasth S, Hulten L. Anal fistulas in Crohn’s disease: incidence and outcome of surgical treatment. Int J Colorectal Dis 1992;7:214-.CrossRefPubMed
19.
Zurück zum Zitat Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003;125:1508-0.CrossRefPubMed Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003;125:1508-0.CrossRefPubMed
20.
Zurück zum Zitat Halme L, Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn’s disease. Dis Colon Rectum 1995;38:55-.CrossRefPubMed Halme L, Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn’s disease. Dis Colon Rectum 1995;38:55-.CrossRefPubMed
21.
Zurück zum Zitat Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976;63:1–12.CrossRefPubMed Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976;63:1–12.CrossRefPubMed
23.
Zurück zum Zitat Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology 1980;79:357-5.PubMed Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology 1980;79:357-5.PubMed
24.
Zurück zum Zitat Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982;83:383-.PubMed Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982;83:383-.PubMed
25.
Zurück zum Zitat Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 1984;79:533-0.PubMed Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 1984;79:533-0.PubMed
26.
Zurück zum Zitat Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971;2:1273-.CrossRefPubMed Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971;2:1273-.CrossRefPubMed
27.
Zurück zum Zitat Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 1985;30:58–64.CrossRefPubMed Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 1985;30:58–64.CrossRefPubMed
28.
Zurück zum Zitat Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology 1990;99:1347-1.PubMed Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology 1990;99:1347-1.PubMed
29.
Zurück zum Zitat Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-.PubMedCrossRef Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-.PubMedCrossRef
30.
Zurück zum Zitat Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci 1994;39:374-0.CrossRefPubMed Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci 1994;39:374-0.CrossRefPubMed
31.
Zurück zum Zitat Hanauer SB, Smith MB. Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 1993;88:646-.PubMed Hanauer SB, Smith MB. Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 1993;88:646-.PubMed
32.
Zurück zum Zitat Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis 1999;5:239-5.PubMedCrossRef Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis 1999;5:239-5.PubMedCrossRef
33.
Zurück zum Zitat Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-in-ano in Crohn’s disease. Results of aggressive surgical treatment. Dis Colon Rectum 1991;34:378-4.CrossRefPubMed Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-in-ano in Crohn’s disease. Results of aggressive surgical treatment. Dis Colon Rectum 1991;34:378-4.CrossRefPubMed
34.
Zurück zum Zitat Vitton V, Gasmi M, Barthet M, Desjeux A, Orsoni P, Grimaud JC. Long-term healing of Crohn’s anal fistulas with fibrin glue injection. Aliment Pharmacol Ther 2005;21:1453-.CrossRefPubMed Vitton V, Gasmi M, Barthet M, Desjeux A, Orsoni P, Grimaud JC. Long-term healing of Crohn’s anal fistulas with fibrin glue injection. Aliment Pharmacol Ther 2005;21:1453-.CrossRefPubMed
35.
Zurück zum Zitat O’Connor L, Champagne BJ, Ferguson MA, Orangio GR, Schertzer ME, Armstrong DN. Efficacy of anal fistula plug in closure of Crohn’s anorectal fistulas. Dis Colon Rectum 2006;49:1569-3.CrossRefPubMed O’Connor L, Champagne BJ, Ferguson MA, Orangio GR, Schertzer ME, Armstrong DN. Efficacy of anal fistula plug in closure of Crohn’s anorectal fistulas. Dis Colon Rectum 2006;49:1569-3.CrossRefPubMed
36.
Zurück zum Zitat Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 2002;359:1541-.CrossRefPubMed Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 2002;359:1541-.CrossRefPubMed
37.
Zurück zum Zitat Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-0.CrossRefPubMed Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-0.CrossRefPubMed
38.
Zurück zum Zitat Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kamm MA. Response of fistulating Crohn’s disease to Infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003;17:387-3CrossRefPubMed Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kamm MA. Response of fistulating Crohn’s disease to Infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003;17:387-3CrossRefPubMed
39.
Zurück zum Zitat Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 2004;10:91-.CrossRefPubMed Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 2004;10:91-.CrossRefPubMed
40.
Zurück zum Zitat Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn’s disease related fistulas after Infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002;5:39–45.CrossRef Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn’s disease related fistulas after Infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002;5:39–45.CrossRef
41.
Zurück zum Zitat Rutgeerts P. Management of perianal Crohn’s disease. Can J Gastroenterol 2000;14(Suppl C):7C–12C.PubMed Rutgeerts P. Management of perianal Crohn’s disease. Can J Gastroenterol 2000;14(Suppl C):7C–12C.PubMed
42.
Zurück zum Zitat Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-3.CrossRefPubMed Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-3.CrossRefPubMed
43.
Zurück zum Zitat Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19–31.CrossRefPubMed Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19–31.CrossRefPubMed
44.
Zurück zum Zitat Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-.CrossRefPubMed Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-.CrossRefPubMed
Metadaten
Titel
Does Infliximab Infusion Impact Results of Operative Treatment for Crohn’s Perianal Fistulas?
verfasst von
Wolfgang B. Gaertner, M.D.
Alejandra Decanini, M.D.
Anders Mellgren, M.D., Ph.D.
Ann C. Lowry, M.D.
Stanley M. Goldberg, M.D.
Robert D. Madoff, M.D.
Michael P. Spencer, M.D.
Publikationsdatum
01.11.2007
Verlag
Springer-Verlag
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 11/2007
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-007-9077-3

Weitere Artikel der Ausgabe 11/2007

Diseases of the Colon & Rectum 11/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.